Next Article in Journal
The Association of IFI27 Expression and Fatigue Intensification during Localized Radiation Therapy: Implication of a Para-Inflammatory Bystander Response
Next Article in Special Issue
Preventive or Potential Therapeutic Value of Nutraceuticals against Ionizing Radiation-Induced Oxidative Stress in Exposed Subjects and Frequent Fliers
Previous Article in Journal
Bioinformatic Prediction of Gene Functions Regulated by Quorum Sensing in the Bioleaching Bacterium Acidithiobacillus ferrooxidans
Previous Article in Special Issue
Exploring the Role of Genetic Variability and Lifestyle in Oxidative Stress Response for Healthy Aging and Longevity
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2013, 14(8), 16917-16942; doi:10.3390/ijms140816917

ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer’s Disease

1
Molecular Pharmacology Unit, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH) Zurich, Zurich CH-8057, Switzerland
2
Institute of Pharmacology and Toxicology, Department of Medicine, University of Zurich, Zurich CH-8057, Switzerland
*
Author to whom correspondence should be addressed.
Received: 17 May 2013 / Revised: 31 July 2013 / Accepted: 12 August 2013 / Published: 16 August 2013
(This article belongs to the Special Issue Oxidative Stress and Ageing)
View Full-Text   |   Download PDF [7506 KB, uploaded 19 June 2014]   |  

Abstract

Increased generation of reactive oxygen species (ROS) is a significant pathological feature in the brains of patients with Alzheimer’s disease (AD). Experimental evidence indicates that inhibition of brain ROS could be beneficial in slowing the neurodegenerative process triggered by amyloid-beta (Abeta) aggregates. The angiotensin II AT1 receptor is a significant source of brain ROS, and AD patients have an increased brain angiotensin-converting enzyme (ACE) level, which could account for an excessive angiotensin-dependent AT1-induced ROS generation. Therefore, we analyzed the impact of ACE inhibition on signs of neurodegeneration of aged Tg2576 mice as a transgenic animal model of AD. Whole genome microarray gene expression profiling and biochemical analyses demonstrated that the centrally active ACE inhibitor captopril normalized the excessive hippocampal ACE activity of AD mice. Concomitantly, the development of signs of neurodegeneration was retarded by six months of captopril treatment. The neuroprotective profile triggered by captopril was accompanied by reduced amyloidogenic processing of the amyloid precursor protein (APP), and decreased hippocampal ROS, which is known to enhance Abeta generation by increased activation of beta- and gamma-secretases. Taken together, our data present strong evidence that ACE inhibition with a widely used cardiovascular drug could interfere with Abeta-dependent neurodegeneration. View Full-Text
Keywords: Alzheimer’s disease; amyloid precursor protein; angiotensin-converting enzyme; AT1 receptor; captopril; neurodegeneration; Tg2576 mouse model Alzheimer’s disease; amyloid precursor protein; angiotensin-converting enzyme; AT1 receptor; captopril; neurodegeneration; Tg2576 mouse model
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Supplementary materials

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

AbdAlla, S.; Langer, A.; Fu, X.; Quitterer, U. ACE Inhibition with Captopril Retards the Development of Signs of Neurodegeneration in an Animal Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2013, 14, 16917-16942.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top